Trial Profile

An Extension Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenia Purpura (ITP)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eltrombopag (Primary)
Indications Idiopathic thrombocytopenic purpura
Focus Adverse reactions
Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

17 Jun 2018 Results assessing the long-term safety and tolerability of Eltrombopag in pediatric patients with previously treated chronic immune thrombocytopenia, presented at the 23rd Congress of the European Haematology Association.
27 Jul 2017 Status changed from recruiting to completed.
13 Jun 2017 Planned End Date changed from 19 Apr 2019 to 1 Jul 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com